Martin Raditsch, CEO, Innovectis GmbH and President of ASTP since May 2019.
Martin is a life scientist and executive leader with 20 years of experience in international business development, licensing and technology transfer in the pharma, med-tech, biotech and material sciences sector and ranging from industry to the public research sector.
Since January 2017 Martin has been CEO of Innovectis GmbH, the knowledge transfer company and 100% subsidiary of Goethe University Frankfurt.
A graduate of Heidelberg University, Martin holds a Ph.D. in Molecular Biology and is certified as RTTP (registered technology transfer professional) by ATTP the global Alliance of Technology Transfer Professionals.
Following his Ph.D., Martin was Laboratory Leader in the pharmaceutical R&D division of BASF AG. After positions in international product marketing of the corporation and plant biotech project management, he became Head of Technology Management Applied Technologies and was responsible for the applied technology portfolio of the plant biotech entity with activities based in the US, Canada, Sweden and Germany.
In 2001, Martin joined EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) a fully owned subsidiary of the European Molecular Biology Laboratory (EMBL)) as Head of Business Development responsible for the commercialisation of intellectual property developed in the EMBL-world including several spin-off projects. As of 2004 he served as Deputy Managing Director of EMBLEM.
In 2011 Martin took on the position as Managing Director at InnovationLab GmbH in Heidelberg. InnovationLab is the joint R&D and transfer institute of the University of Heidelberg, University of Mannheim, BASF, Merck, Heidelberger Printing Press, and SAP.
Martin was involved in the funding process of 16 start-ups and is co-founder of the European Institute for Pharma Logistics (EIPL). He serves currently as an advisory board member of the BioRN Network, as a development committee member of ASTP and as an Advisory Board member of BioMed X GmbH.